Clinical Trial Update: Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

View source ↗

Summary

AstraZeneca-sponsored clinical trial evaluating transthyretin amyloidosis cardiomyopathy in patients with heart failure with preserved ejection fraction (HFpEF)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Transthyretin Amyloidosis Cardiomyopathy

Snippet

Sponsor: AstraZeneca | Conditions: Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction | Status: TERMINATED